Zydus Cadila’s COVID-19 drug succeeds in Phase II Indian trials


Zydus Cadila’s Pegylated Interferon alpha-2b, PegiHep, was originally approved for Hepatitis C and was launched in the Indian market in 2011; it was repurposed for treating moderate COVID-19 patients

Source

Leave a Reply